| Identification | Back Directory | [Name]
Sacubitril Impurity 7 | [CAS]
149709-44-4 | [Synonyms]
LBQ657
LCZ696-4
Sacubitrilat
Deethyl Sakuba
LCZ-696 Impurity 1
Diacid of Sacubitril
LCZ696 Impurity 900-04
Sacubitrilat (LBQ-657)
Sacubitril Desethyl Impurity
Sacubitril metabolite LBQ 657
(2R,4S)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(3-carboxypropanamido)- 2-methylpentanoic aci
[1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-, (αR,γS)-
4-[[(1S,3R)-1-[([1,1'-Biphenyl]-4-yl)methyl]-3-methyl-4-hydroxy-4-oxobutyl]amino]-4-oxobutanoic acid | [Molecular Formula]
C22H25NO5 | [MDL Number]
MFCD00921225 | [MOL File]
149709-44-4.mol | [Molecular Weight]
383.44 |
| Chemical Properties | Back Directory | [Boiling point ]
705.4±60.0 °C(Predicted) | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMF:30.0(Max Conc. mg/mL);78.24(Max Conc. mM)
DMSO:77.0(Max Conc. mg/mL);200.81(Max Conc. mM)
Ethanol:77.0(Max Conc. mg/mL);200.81(Max Conc. mM)
Ethanol:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.3(Max Conc. mM) | [form ]
A crystalline solid | [pka]
4.59±0.23(Predicted) | [color ]
White to off-white | [Optical Rotation]
[α]/D -35 to -27°, c =1 in methanol | [InChIKey]
DOBNVUFHFMVMDB-BEFAXECRSA-N | [SMILES]
OC(CCC(N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@H](C(O)=O)C)=O)=O |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H315-H319-H335 | [Precautionary statements ]
P261-P305+P351+P338 | [WGK Germany ]
WGK 3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
STOT RE 1
STOT SE 3 |
| Hazard Information | Back Directory | [Uses]
Desethyl Sacubitril is an impurity in the synthesis of Sacubitril (S080895), an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure. | [Biological Activity]
LBQ657 is the active metabolite of sacubitril. It is an inhibitor of the enkephalinase neprilysin (neutral endopeptidaseNEP) formed by the action of esterases on its prodrug sacubitril (AHU377)which is half of the heart failure combination drug Entrestoalong with the angiotensin-receptor blocker Valsartan. LBQ657 prevents neprilysinμs degradation of atrial and brain natriuretic peptidetwo blood pressure lowering peptides. |
|
| Company Name: |
DebyeTec.com Inc.
|
| Telephone: |
18086626237 18086626237 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList16955/0.htm |
| Company Name: |
Roark Standards
|
| Telephone: |
0755-83552066 15986688328 |
| Website: |
roarkstandards.com |
|